Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index

The Lancet

Volumn 374, Issue 9691, 2009, Pages 704-711

  Puhan, Milo A ^a,b   Garcia Aymerich, Judith ^c,d,e,f   Frey, Martin ^g   ter Riet, Gerben ^h   Antó, Josep M ^c,d,e,f   Agustí, Alvar G ^i,j   Gómez, Federico P ^j,k   Rodríguez Roisín, Roberto ^i,j   Moons, Karel GM ^l   Kessels, Alphons G ^m   Held, Ulrike ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g Klinik Barmelweid   (Switzerland)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m Clinical Epidemiology   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; CALIBRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; EXERCISE TOLERANCE; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK; VALIDATION STUDY;

EID: 69149083159     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61301-5     Document Type: Article

References (40)

1. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012
2. Fabbri L.M., and Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 370 (2007) 797-799
3. Mannino D.M., and Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370 (2007) 765-773
4. Cote C.G., Pinto-Plata V.M., Marin J.M., Nekach H., Dordelly L.J., and Celli B.R. The modified BODE index: validation with mortality in COPD. Eur Respir J 32 (2008) 1269-1274
5. Imfeld S., Bloch K.E., Weder W., and Russi E.W. The BODE index after lung volume reduction surgery correlates with survival. Chest 129 (2006) 873-878
6. Martinez F.J., Han M.K., Andrei A.C., et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 178 (2008) 491-499
7. Moons K.G., Royston P., Vergouwe Y., Grobbee D.E., and Altman D.G. Prognosis and prognostic research: what, why, and how?. BMJ 338 (2009) b375
8. Altman D.G., and Royston P. What do we mean by validating a prognostic model?. Stat Med 19 (2000) 453-473
9. Bleeker S.E., Moll H.A., Steyerberg E.W., et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 56 (2003) 826-832
10. Altman D.G., Vergouwe Y., Royston P., and Moons K.G. Prognosis and prognostic research: validating a prognostic model. BMJ 338 (2009) b605
11. Garcia-Aymerich J., Gomez F.P., and Anto J.M. Phenotypic characterization and course of chronic obstructive pulmonary disease in the PAC-COPD study: design and methods. Arch Bronconeumol 45 (2009) 4-11
12. Puhan M.A., Busching G., Schunemann H.J., VanOort E., Zaugg C., and Frey M. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 145 (2006) 816-825
13. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 117 suppl 2 (2000) 398S-401S
14. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
15. Balcells E., Anto J.M., Gea J., et al. Characteristics of patients admitted for the first time for COPD exacerbation. Respir Med (2009) 10.1016/j.rmed.2009.04.001 published online May 7.
16. Puhan M.A., Behnke M., Frey M., et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes 2 (2004) 1
17. Duiverman M.L., Wempe J.B., Bladder G., Kerstjens H.A., and Wijkstra P.J. Health-related quality of life in COPD patients with chronic respiratory failure. Eur Respir J 32 (2008) 379-386
18. Eltayara L., Becklake M.R., Volta C.A., and Milic-Emili J. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154 (1996) 1726-1734
19. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
20. Donders A.R., van der Heijden G.J., Stijnen T., and Moons K.G. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59 (2006) 1087-1091
21. Yang X., So W.Y., Tong P.C., et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 168 (2008) 451-457
22. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
23. Janssen K.J., Moons K.G., Kalkman C.J., Grobbee D.E., and Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol 61 (2008) 76-86
24. Steyerberg E.W., Borsboom G.J., van Houwelingen H.C., Eijkemans M.J., and Habbema J.D. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med 23 (2004) 2567-2586
25. van Houwelingen H.C. Validation, calibration, revision and combination of prognostic survival models. Stat Med 19 (2000) 3401-3415
26. Sauerbrei W., Royston P., and Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26 (2007) 5512-5528
27. Copas J.B. Using regression models for prediction: shrinkage and regression to the mean. Stat Methods Med Res 6 (1997) 167-183
28. Royston P., Moons K.G., Altman D.G., and Vergouwe Y. Prognosis and prognostic research: Developing a prognostic model. BMJ 338 (2009) b604
29. Sullivan L.M., Massaro J.M., and D'Agostino Sr. R.B. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 23 (2004) 1631-1660
30. Puhan M.A., Mador M.J., Held U., Goldstein R., Guyatt G.H., and Schunemann H.J. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 32 (2008) 637-643
31. Pinto-Plata V.M., Cote C., Cabral H., Taylor J., and Celli B.R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23 1 (2004) 28-33
32. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003) 544-549
33. Steyerberg E.W., Bleeker S.E., Moll H.A., Grobbee D.E., and Moons K.G. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 56 (2003) 441-447
34. Eichler K., Puhan M.A., Steurer J., and Bachmann L.M. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 153 (2007) 722-731
35. de Torres J.P., Pinto-Plata V., Casanova C., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133 (2008) 1336-1343
36. Man S.F., Xing L., Connett J.E., et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?. Eur Respir J 32 (2008) 1451-1457
37. Marrugat J., D'Agostino R., Sullivan L., et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 57 (2003) 634-638
38. Puhan M.A., Zoller M., and ter Riet G. COPD: more than respiratory. Lancet 371 (2008) 27-28
39. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 suppl 5 (2005) v1-v52
40. Moons K.G., Altman D.G., Vergouwe Y., and Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338 (2009) b606